Skip to main content
Clinical Trials/NCT01229540
NCT01229540TerminatedNot Applicable

Clinical Research on Retinal Neovascularization of Diabetic Retinopathy

Tianjin Medical University1 site in 1 countryStarted: October 27, 2010Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Terminated
Sponsor
Locations
1

Study Overview

Brief Summary

Retinal neovascularization of diabetic retinopathy might be associated with genetic risk factors and environmental risk factors.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
45 Years to 74 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • T2DM was diagnosed according to the World Health Organization Expert Consultation Report 1999 and consisted of one of the following: fasting blood glucose (FBG) ≥7.0 mmol/L (≥126 mg/dL), blood glucose ≥11.1 mmol/L (≥200 mg/dL) 2 hours after an oral glucose tolerance test (OGTT); or a random blood glucose ≥11.1 mmol/L (≥200 mg/dL).
  • DR was clinically graded in accordance with the International Clinical Diabetic Retinopathy guidelines based on fundus fluorescence angiography.
  • All participants with PDR underwent a comprehensive dilated fundus examination to detect DR by indirect ophthalmoscopy and were diagnosed by fundus fluorescence angiography.

Exclusion Criteria

  • Patients were excluded if they had acute complications of diabetes mellitus, type 1 diabetes mellitus, other types of diabetes, serious cardiovascular, hepatic, nephritic or other complications, other serious primary diseases or mental illness.

Investigators

Sponsor
Tianjin Medical University
Sponsor Class
Other

Study Sites (1)

Loading locations...

Similar Trials